<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095314</url>
  </required_header>
  <id_info>
    <org_study_id>Booster Penta 0413</org_study_id>
    <nct_id>NCT02095314</nct_id>
  </id_info>
  <brief_title>Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine</brief_title>
  <official_title>Antibody Persistence After Primary Doses, Immune Response and Safety After Doses of Pentabio Vaccine in Indonesian Children at 18-24 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Measure antibody persistence prior to booster administration of Pentabio vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Number and percentage of children with anti diphtheria, titer and anti tetanus titer &gt;= 0.01
      IU/ml, anti HBs &gt;=10mIU/ml, anti Hib &gt;=0.15ug/ml prior to booster administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geomoteric mean titer prior to booster administration of Pentabio vaccine</measure>
    <time_frame>visit 1</time_frame>
    <description>The number and percentage of children with anti diphtheria titer and anti tetanus titer &gt;=0.01 IU/ml anti HBs &gt;=10 mIU/ml, anti Hib &gt;=0.15 ug/ml prior to booster administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protectivity of Pentabio vaccine 1 month after the booster dose</measure>
    <time_frame>1 month</time_frame>
    <description>Serological response to diphtheria, tetanus, pertussis and Hib (Geometric Mean Titer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological response to diphtheria, tetanus, pertussis, hepatitis B and PRP-T before and 1 month after the booster dose</measure>
    <time_frame>1 month</time_frame>
    <description>Geometric mean titer to diphtheria, tetanus, pertussis, Hepatitis B and Hib before immunization and 1 month after immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion and seroprotection before and 1 month after the booster dose</measure>
    <time_frame>1 month</time_frame>
    <description>The changes of serological response before and after booster dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Local and systemic reaction within 28 days after immunization.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">399</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pentavalen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentavalen</intervention_name>
    <description>Batch 5010613</description>
    <arm_group_label>Pentavalen</arm_group_label>
    <other_name>Pentabio vaccine</other_name>
    <other_name>DPT-HB-Hib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children, 18-24 months of age

          -  Subjects who had completed the primary series of Pentabio vaccine in the previous
             trial

          -  Father, mother, or legally acceptable representative have been informed properly
             regarding the study and signed the informed consent form

          -  Subject's parents commit to comply with the instruction

        Exclusion Criteria:

          -  Subjects concomitantly enrolled or scheduled to be enrolled in another trial

          -  Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axillary temperature &gt;=37.5oC on Day 0)

          -  Known history of uncontrolled coagulopathy or blood disorders contraindicating
             intramuscular injection

          -  Known history of allergy to any component of the vaccines (e.f. formaldehyde)

          -  Known history of acquired immunodeficiency (including HIV infection)

          -  Subject who has received a treatment likely to alter immune response in the previous 4
             weeks (e.g intravenous immunoglobulin, blood-derived products or long term
             corticotherapy (&gt;2 weeks)

          -  Subject receives other vaccination within 1 month prior to inclusion

          -  Any abnormality or chronic disease justified by investigator that might interfere
             assessment of the trial objectives

          -  Infant with a known history of diphtheria, tetanus, pertussis, Hepatitis B and Hib
             infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kusnandi Rusmil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Child Health, School of Medicine Padjadjaran University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hartono Gunardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Child Health, School of Medicine, University of Indonesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Garuda Primary Health Center</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibrahim Adjie Primary Health Center</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puter Primary Health Centre</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jatinegara Primary Health Center</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mampang Prapatan Primary Health Center</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tebet Primary Health Center</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DTP-HB-Hib</keyword>
  <keyword>Pentavalen</keyword>
  <keyword>Pentabio</keyword>
  <keyword>Booster</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

